Cargando…
Tolvaptan for the treatment of the syndrome of inappropriate antidiuresis (SIAD)
The syndrome of inappropriate antidiuresis (SIAD), the commonest cause of hyponatraemia, is associated with significant morbidity and mortality. Tolvaptan, an oral vasopressin V2-receptor antagonist, leads through aquaresis to an increase in serum sodium concentration and is the only medication lice...
Autores principales: | Tzoulis, Ploutarchos, Kaltsas, Gregory, Baldeweg, Stephanie E., Bouloux, Pierre-Marc, Grossman, Ashley B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10192810/ https://www.ncbi.nlm.nih.gov/pubmed/37214762 http://dx.doi.org/10.1177/20420188231173327 |
Ejemplares similares
-
Therapy for SIAD: what does the future hold?
por: Tzoulis, Ploutarchos
Publicado: (2023) -
Improving care and outcomes of inpatients with syndrome of inappropriate antidiuresis (SIAD): a prospective intervention study of intensive endocrine input vs. routine care
por: Tzoulis, Ploutarchos, et al.
Publicado: (2016) -
Association of hyponatremia with bone mineral density and fractures: a narrative review
por: Tzoulis, Ploutarchos, et al.
Publicado: (2023) -
Hyponatraemia and the syndrome of inappropriate antidiuresis (SIAD) in cancer
por: Donald, D Mc, et al.
Publicado: (2022) -
MANAGEMENT OF ENDOCRINE DISEASE: Dysnatraemia in COVID-19: prevalence, prognostic impact, pathophysiology, and management
por: Tzoulis, Ploutarchos, et al.
Publicado: (2021)